
Bayer reports positive early data for Parkinson’s cell therapy
The therapy, developed by Bayer’s Bluerock Therapeutics subsidiary, appeared safe and well-tolerated in a 12-person clinical trial. Published Aug. 28, 2023
The therapy, developed by Bayer’s Bluerock Therapeutics subsidiary, appeared safe and well-tolerated in a 12-person clinical trial. Published Aug. 28, 2023